Liver cirrhosis and its treatment

Česká verzia

Authors: J. Lata; T. Vaňásek; O. Stibůrek
Authors place of work: Interní hepatogastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jan Lata, CSc.
Published in the journal: Vnitř Lék 2009; 55(9): 774-778
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Summary

Cirrhosis is an end-stage liver disease. It is necessary to always search for the cause, attempt to initiate suitable causal treatment and assess the severity of hepatopathy by evaluating hepatic functional reserve (according to the Child-Pugh classification). It is necessary to continually monitor possible complications of cirrhosis, some can be prevented. Regular clinical and laboratory monitoring as well as ultrasound and endoscopic examinations are required. The paper discusses the treatment of the disease as well as its complications. Cure can only be achieved with a liver transplant; this option should be evaluated by a hepatologist in each patient with functional classification B or with serious complications of portal hypertension mentioned above. Treatment standards compiled by the Czech Society of Hepatology (http://www.ceska-hepatologie.cz) offer the basic algorithms of correct diagnosis and treatment.

Key words:
liver cirrhosis – portal hypertension – bleeding oesophageal varices – ascites – spontaneous bacterial peritonitis – hepatorenal syndrome – hepatocellular carcinoma

Zdroje

1. Sherlocková S, Dooley J. Nemoci jater a žlučových cest. 11. vyd. Hradec Králové: Olga Čermáková publishing 2004.

2. Brůha R, Drastich P, Hůlek P et al. Diagnostika a léčba jaterní encefalopatie. Vnitř Lék 2006; 52: 85–86.

3. Parés A, Caballería I, Rodés J et al. Long-term effects of ursodeoxycholic acidin primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561–566.

4. Jacobs BP, Dennehy C, Ramirez G et al. Milk thistle for the treatment of liver diseases: a systematic review and meta-analysis. Am J Med 2002; 113: 506–515.

5. Brůha R, Mareček Z. Esenciální fosfolipidy v léčbě jaterní encefalopatie. Vnitř Lék 2000; 46: 199–204.

6. Lata J, Kroupa R, Novotný I et al. Akutní krvácení z horní části gastrointestinálního traktu. Vnitř Lék 2009; 55 (Suppl 1): S29–S33.

7. Imazu H, Seewald S, Omar S et al. Endoscopic Treatment for Portal Hypertension: What’s New in the Last 12 Months? Endoscopy 2005; 37: 116–121.

8. Møller S, Henriksen JH, Bendtsen F. Ascites: Pathogenesis and therapeutic principles. Scand J Gastroenterol 2009; 8: 902–911.

9. Khan J, Pikkarainen P, Karvonen AL et al. Ascites: Aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. Scand J Gastroenterol 2009; 8: 970–974.

10. Brůha R, Balihar K, Drastich P et al.Doporučený postup pro diagnostiku a léčbuhepatorenálního syndromu. Vnitř Lék 2006; 52: 649–650.

11. Rougier P, Mitry E, Barbare JC et al. Hepatocellular carcinoma (HCC): an update. Semin Oncol 2007; 34 (2 Suppl 1): S12–S20.

12. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary Syndrome – A Liver-Induced Lung Vascular Disorder. N Engl J Med 2008; 358: 2378–2387.